COMMUNIQUÉS West-GlobeNewswire

HalioDx : HalioDx highlights use of Immunosign® to define CAR T-cell therapy signature in tumor at ASCO 2017

05/06/2017 - 15:00

HalioDx highlights use of Immunosign® to define CAR T-cell therapy signature in tumor at ASCO 2017 For the first time, a tumor microenvironment immune gene signature associated with CAR T-cell treatment of non-Hodgkin [...]

Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

05/06/2017 - 15:00

Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia Analysis shows statistically [...]

Silmäasema Oyj's public offering has been oversubscribed and the subscription period discontinued

05/06/2017 - 15:00

Stock Exchange Release 5 June 2017, at 4 p.m. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, SOUTH AFRICA, SINGAPORE OR JAPAN OR ANY [...]

Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer

05/06/2017 - 13:15

Collaboration will use real-world patient data and cognitive computing with aim of improving outcomes in advanced breast cancer Brings Novartis innovation and breast cancer expertise together with IBM Watson Health [...]

Summit Presents Positive New Preclinical Data on Novel CDI Antibiotic Ridinilazole at ASM Microbe 2017

05/06/2017 - 13:00

Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT PRESENTS POSITIVE NEW PRECLINICAL DATA ON NOVEL CDI ANTIBIOTIC RIDINILAZOLE AT ASM MICROBE 2017 Oxford, UK, 5 June 2017 - Summit Therapeutics plc (NASDAQ: SMMT [...]

Immunocore Announces Compelling Single Agent IMCgp100 Clinical Data in Metastatic Uveal Melanoma at ASCO 2017 Annual Meeting

05/06/2017 - 13:00

PRESS RELEASE Immunocore Announces Compelling Single Agent IMCgp100 Clinical Data in Metastatic Uveal Melanoma at ASCO 2017 Annual Meeting Median progression free survival (PFS) close to double the reported median PFS [...]

Nexstim Plc Members of the Board Committees

05/06/2017 - 13:00

Company announcement, Helsinki, 5 June 2017 at 2:00 pm Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), a medical technology company developing and marketing pioneering navigated non-invasive brain [...]

Michael Phelps, World Champion Athlete and Mental Health Advocate, Appointed to Medibio Board of Directors

05/06/2017 - 12:00

SYDNEY, Australia, June 05, 2017 (GLOBE NEWSWIRE) -- Medibio Limited (ASX:MEB) (MEB or the Company), an ASX listed medical technology company that has developed an effective objective test to assist in the diagnosis of [...]

Innate Pharma acquiert l'anti-C5aR, un anticorps en Phase clinique, auprès de Novo Nordisk A/S

02/06/2017 - 22:26

INNATE PHARMA RENFORCE SON PORTEFEUILLE D'ANTICORPS PROPRIÉTAIREs AVEC L'ACQUISITION DE L'ANTI-C5 aR, UN ANTICORPS AU STADE CLINIQUE, AUPRÈS DE NOVO NORDISK A/S L'anti-C5aR est un anticorps thérapeutique « first-in- [...]

Souris dans l'espace : des souris de Taconic incluses dans le lancement vers la Station spatiale internationale

02/06/2017 - 22:21

HUDSON, New York, le 2 e juin 2017 (GLOBE NEWSWIRE) - Lorsque l'astronef SpaceX Dragon sera lancé aujourd'hui vers la Station spatiale internationale, il sera rejoint par 40 souris spéciales, élevées spécifiquement pour [...]

Virbac : Déclaration d'actions et de droits de vote au 31 Mai 2017

02/06/2017 - 13:46

DECLARATION D'ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d'actions composant le capital (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) [...]

Virbac : Declaration of the number of shares and voting rights as of May 2017, 31.

02/06/2017 - 13:46

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]

XBiotech présente des résultats de phase III pour son traitement par anticorps du cancer colorectal lors de la réunion ASCO de 2017

02/06/2017 - 13:45

Les données montrent une moindre progression de la maladie et une survie améliorée pour les patients atteignant le critère d'évaluation principal AUSTIN, Texas, le 1 er juin 2017 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ [...]

Nexstim Plc Agrees on Extension of Tekes R&D Loan Repayments

02/06/2017 - 13:30

Company announcement, Helsinki, 2 June 2017 at 2:30 pm Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), a medical technology company developing and marketing pioneering navigated non-invasive brain [...]

Crown Bioscience affiche une maîtrise approfondie des modèles PDX et une expertise émergente en immuno-oncologie

02/06/2017 - 10:39

Avancées scientifiques en immuno-oncologie post-AACR SANTA CLARA, Californie, 2017-06-02 (GLOBE NEWSWIRE) - Crown Bioscience , une filiale en propriété exclusive de Crown Bioscience International (TWSE : code boursier [...]

Orion Diagnostica's co-operation negotiations in Oulu completed

02/06/2017 - 10:06

ORION CORPORATION PRESS RELEASE 2 JUNE 2017 at 11.06 a.m. EEST Orion Diagnostica's co-operation negotiations in Oulu completed The co-operation negotiations which were initiated in April in Orion Diagnostica Oy, a [...]

Zealand to present at two international healthcare investor conferences in June 2017

02/06/2017 - 09:26

Press Release - No. 4 / 2017 Zealand to present at two international healthcare investor conferences in June 2017 Copenhagen, June 2, 201 7 - Zealand announces that its President and CEO, Britt Meelby Jensen, and [...]

Tecan appoints Erik Norström Head of Corporate Development

02/06/2017 - 07:25

Männedorf, Switzerland, June 2, 2017 - The Tecan Group (SIX Swiss Exchange: TECN) announced today that Erik Norström has been appointed Head of Corporate Development and a member of the Management Board. He will assume [...]

Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer

02/06/2017 - 07:15

At a subsequent analysis of the MONALEESA-2 trial, after nearly one year of additional follow-up, Kisqali plus letrozole demonstrated median progression-free survival (PFS) of 25.3 months compared to 16.0 months for [...]